In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study
Genentech put the A team on their PD-L1 checkpoint program for Tecentriq (atezolizumab), building a pipeline of combinations now in the clinic as they raced to an accelerated approval so they could begin marketing in the booming field. And this morning, Roche says that the drug failed the late-stage confirmatory study in bladder cancer, failing to significantly improve overall survival and delivering a blow that raises questions about the fate of this drug and their entire checkpoint R&D campaign.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.